Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
20 Results for "
Transduction complex
" in MedChemExpress (MCE) Product Catalog:
Products (20)
20 Results for "Transduction complex" in MCE Product Catalog:
106
106 Publications Verification
Synonyms: FK506; Fujimycin; FR900506
106
106 Publications Verification
Synonyms: FK506 monohydrate; Fujimycin monohydrate; FR900506 monohydrate
58
58 Cited Publications
MRTX1133 is a noncovalent, potent, and selective alkyne-based KRAS G12D inhibitor. MRTX1133 optimally fills the switch II pocket and extends three substituents to favorably interact with the protein, resulting in an estimated KD against KRAS G12D of 0.2 pM. MRTX1133 prevents SOS1-catalyzed nucleotide exchange and/or formation of the KRAS G12D/GTP/RAF1 complex, thereby inhibiting mutant KRAS-dependent signal transduction. MRTX1133 selectively inhibits KRAS G12D mutant, but not KRAS wild-type, tumor cells. MRTX1133 has single digit nanomolar activity in cellular assays and marked in vivo efficacy in tumor models harboring KRAS G12D mutations .
1
1 Cited Publications
Synonyms: FK506-13C,d2; Fujimycin-13C,d2; FR900506-13C,d2
Art. -Nr.: HY-W015954
CAS. Nr.: 24347-58-8
Art. -Nr.: HY-13756R
CAS. Nr.: 104987-11-3
Synonyms: FK506 (Standard); Fujimycin (Standard); FR900506 (Standard)
Art. -Nr.: HY-P991201
Target:
Forschungsgebiete:
Art. -Nr.: HY-13756S2
Synonyms: FK506-d3; Fujimycin-d3; FR900506-d3
Art. -Nr.: HY-P4087
CAS. Nr.: 1417221-06-7
Art. -Nr.: HY-P4108C
Target:
Forschungsgebiete:
Art. -Nr.: HY-P4096
CAS. Nr.: 329004-38-8
Target:
Forschungsgebiete:
Art. -Nr.: HY-P4087B
Art. -Nr.: HY-W015954R
CAS. Nr.: 24347-58-8
Art. -Nr.: HY-134813A
MRTX1133 formic is a noncovalent, potent, and selective KRAS G12D inhibitor. MRTX1133 formic optimally fills the switch II pocket and extends three substituents to favorably interact with the protein, resulting in an estimated KD against KRAS G12D of 0.2 pM. MRTX1133 formic prevents SOS1-catalyzed nucleotide exchange and/or formation of the KRASG12D/GTP/RAF1 complex, thereby inhibiting mutant KRAS-dependent signal transduction. MRTX1133 formic shows efficacy in tumor models harboring KRAS G12D mutations .
Art. -Nr.: HY-162816
PROTAC HPK1 Degrader-3 is an orally active HPK1 PROTAC degrader with a DC50 of 21.26 nM. PROTAC HPK1 Degrader-3 induces HPK1 degradation via the ubiquitin-proteasome system and forms a stable ternary complex with HPK1 and CRBN. PROTAC HPK1 Degrader-3 inhibits the SLP76 and NF-κB signaling pathways, enhances the transduction of the MAPK signaling pathway, and promotes the secretion of T cell immune cytokines. PROTAC HPK1 Degrader-3 inhibits tumor growth and enhances the anti-tumor efficacy of anti-PD-L1 therapy. PROTAC HPK1 Degrader-3 can be used in the research of colon cancer .
Art. -Nr.: HY-P991804
Target:
Forschungsgebiete:
Art. -Nr.: HY-186087
CAS. Nr.: 3058972-05-4
Target:
Forschungsgebiete:
RM-046 is an orally active, selective ternary complex inhibitor of KRAS Q61H (active form). RM-046 forms a ternary complex with cyclophilin A, binds to active KRAS Q61H in a non-covalent manner, blocks effector binding via steric hindrance and inhibits downstream signal transduction. RM-046 inhibits ERK phosphorylation and cancer cell proliferation, and induces sustained RAS pathway signal inhibition, anti-tumor activity and tumor regression in preclinical xenograft models. RM-046 can be used for the research of KRAS Q61H mutant cancers .
Art. -Nr.: HY-182067
Forschungsgebiete:
anti-TNBC agent-15 is a platinum (IV) complex with anti-triple-negative breast cancer activity. anti-TNBC agent-15 inhibits cancer cell viability. anti-TNBC agent-15 reverses the resistance of triple-negative breast cancer cells to Cisplatin (HY-17394), increases intracellular uptake, and effectively triggers apoptosis by inducing DNA damage, enhancing intracellular ROS accumulation and activating the mitochondrial pathway. anti-TNBC agent-15 enhances lipid peroxidation, interferes with the signal transduction of the cystine/glutamate transporter-glutathione peroxidase axis, and induces ferroptosis. anti-TNBC agent-15 significantly inhibits tumor growth in triple-negative breast cancer/Cisplatin xenograft models. anti-TNBC agent-15 can be used for the research of triple-negative breast cancer .
Art. -Nr.: HY-P11580
Target:
Forschungsgebiete:
Art. -Nr.: HY-P992061
Target:
Forschungsgebiete:
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
